Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing.

Torstein Tengs1, Jeff C Lee, J Guillermo Paez

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA. torstein.tengs@vetinst.no

Cancer Letters
|September 21, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interplay between disinfection and the enigmatic diplomonad parasite Spironucleus salmonicida in Atlantic salmon.

Scientific reports·2026
Same author

Mutational signatures in hematological malignancies.

Einstein (Sao Paulo, Brazil)·2026
Same author

<i>In vivo</i> multiplexed modeling reveals diverse roles of the TBX2 subfamily and <i>Egr1</i> in <i>Kr</i> <i>as</i>-driven lung adenocarcinoma.

Genes & diseases·2026
Same author

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

The Journal of clinical investigation·2026
Same author

Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression.

Nature communications·2025
Same author

Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Nature medicine·2025

This study evaluated cancer gene resequencing microarrays, finding high accuracy with low false positives. The platform detected both germline and somatic mutations in non-small cell lung cancer (NSCLC) samples.

Area of Science:

  • Genomics
  • Molecular Biology
  • Oncology

Background:

  • Cancer gene interrogation requires accurate mutation detection platforms.
  • Resequencing microarrays offer a high-throughput approach for genetic analysis.

Purpose of the Study:

  • To assess the performance of resequencing microarrays for interrogating cancer-associated genes.
  • To determine false positive and negative rates of the microarray platform.
  • To identify mutations in non-small cell lung cancer (NSCLC) samples.

Main Methods:

  • Design of resequencing microarrays targeting 164 cancer gene exons.
  • Dideoxy sequencing for validation of array data across 335,420 bases.
  • Analysis of 20 non-small cell lung cancer (NSCLC) samples using the microarrays.

Related Experiment Videos

  • MALDI-TOF genotyping for mutation characterization.

    • Main Results:

    • Microarray calls covered approximately 97.5% of interrogated bases with very low false positive rates.
    • False negative rate for heterozygous mutations was 1.41%.
    • Homozygous mutations were detected, but 8.11% were misclassified as heterozygous.
    • Somatic and germline mutations were identified in NSCLC samples, including two MET mutations.

    Conclusions:

    • Resequencing microarrays demonstrate high performance for cancer gene analysis with acceptable accuracy.
    • The platform successfully identified clinically relevant mutations in NSCLC, including potential cancer-driving genotypes.
    • Distinguishing true pathogenic mutations from common germline polymorphisms is crucial for clinical application.